Real-world outcomes of faricimab in treating diabetic macular edema up to two years
Faricimab significantly reduced CMT in both groups, with a greater reduction in treatment-naive eyes. VA improvement was, however, not statistically significant. Further studies are warranted to explore factors influencing visual outcomes.
Authors
- Priyancaa Jeyabaladevan
- Tanvi Khetan (ORCID: https://orcid.org/0000-0002-2203-9614)
- Syed Ahmed (ORCID: https://orcid.org/0000-0001-7109-7143)
- Prachi Shah (ORCID: https://orcid.org/0000-0003-3467-8816)
- Sejal Vithlani
Institutions
- Barts Health NHS Trust (GB)
Publication Details
- Journal
- Indian Journal of Ophthalmology
- Published
- 2025-10-28
- DOI
- https://doi.org/10.4103/ijo.ijo_930_25
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00